New combo therapy targets hard-to-treat tumors
NCT ID NCT04750954
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 32 times
Summary
This early-phase trial tests a new drug (peposertib) combined with a radioactive treatment (lutetium Lu 177 dotatate) for people with a type of neuroendocrine tumor. The goal is to find the safest and most effective dose, and to see if the combination can shrink tumors or slow their growth. About 29 adults with well-differentiated, somatostatin receptor-positive tumors are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.